The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is underway on behalf of DRUG investors who suffered losses. NEW YORK, Nov. 2,...
Hence then, the article about bright minds biosciences investigation notice levi korsinsky notifies investors of pending investigation into bright minds biosciences drug was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG) )
Also on site :
- Kraft Mac & Cheese Just Launched 2 Unexpected New Flavors—and One Is Inspired by a Beloved Breakfast Treat
- Popular Toddler Snacks Sold at Costco, Target and Walmart Recalled Over Potentially Deadly Choking Hazard
- Grand Circle Cruise Line Black Friday Sale: Save Up to $3,000 on 2027 River Cruises, Plus $1,000 Off for Solo Travelers